Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AVTX
stocks logo

AVTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
0.00
-100%
-1.443
-81.85%
--
--
-1.610
+28.8%
--
--
-1.505
-21.61%
Estimates Revision
The market is revising No Change the revenue expectations for Avalo Therapeutics, Inc. (AVTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 54.74%.
EPS Estimates for FY2025
Revise Upward
up Image
+25.44%
In Past 3 Month
Stock Price
Go Up
up Image
+54.74%
In Past 3 Month
Wall Street analysts forecast AVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTX is 37.00 USD with a low forecast of 25.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast AVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTX is 37.00 USD with a low forecast of 25.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 17.950
sliders
Low
25.00
Averages
37.00
High
48.00
Current: 17.950
sliders
Low
25.00
Averages
37.00
High
48.00
Oppenheimer
Oppenheimer
Outperform
maintain
$35
2025-09-15
Reason
Oppenheimer
Oppenheimer
Price Target
$35
2025-09-15
maintain
Outperform
Reason
Oppenheimer recommends investors to be buyers of Avalo Therapeutics in anticipation of the presentation of lutikizumab's open-label Phase 2 data in about 40 treatment-naive hidradenitis suppurativa patients late this week. The firm, which forecasts "strong results for luti" at the EADV conference given its substantial benefit previously shown in a difficult-to-treat, TNF-refractory disease population, would expect '009 - with its multiple advantages over luti - to show "at least as good as, and potentially better, efficacy" when LOTUS reads out in mid-2026, says the analyst. The firm has an Outperform rating and $35 price target on Avalo shares.
TD Cowen
Stacy Ku
Buy
initiated
2025-09-05
Reason
TD Cowen
Stacy Ku
Price Target
2025-09-05
initiated
Buy
Reason
TD Cowen analyst Stacy Ku initiated coverage of Avalo Therapeutics with a Buy rating and no price target. The company's AVTX-009 is in a Phase II trial for hidradenitis suppurativa, with data expected in mid-2026, the analyst tells investors in a research note. The firm says key opinion leaders highlight the heterogeneous patient population and high unmet need. The leaders expect success with AVTX-009 with potential for a $1B-plus sales opportunity.
Cantor Fitzgerald
Prakhar Agrawal
Overweight
initiated
2025-08-15
Reason
Cantor Fitzgerald
Prakhar Agrawal
Price Target
2025-08-15
initiated
Overweight
Reason
Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of Avalo Therapeutics with an Overweight rating and no price target. Avalo is a clinical-stage biotech company focused on autoimmune diseases, the analyst tells investors in a research note. The firm says the company's lead drug AVTX-009 is an IL-1N2 antibody currently in a Phase 2 trial for hidradenitis suppurativa with a readout expected in mid-2026.
H.C. Wainwright
Mitchell Kapoor
initiated
$15
2025-06-02
Reason
H.C. Wainwright
Mitchell Kapoor
Price Target
$15
2025-06-02
initiated
Reason
H.C. Wainwright analyst Mitchell Kapoor assumed coverage of Avalo Therapeutics with a Buy rating and $15 price target. Avalo is a clinical-stage biotech company developing therapeutics for immunological diseases, the analyst tells investors in a research note. The firm says AVTX-009 is initially being developed to treat hidradenitis suppurativa, which is a large indication with an evolving standard-of-care regimen.
Jefferies
Kambiz Yazdi
Strong Buy
Initiates
$23
2025-03-25
Reason
Jefferies
Kambiz Yazdi
Price Target
$23
2025-03-25
Initiates
Strong Buy
Reason
Jefferies analyst Kambiz Yazdi initiated coverage of Avalo Therapeutics with a Buy rating and $23 price target. Avalo is a clinical stage biotechnology company focused on immunology and inflammation led by a veteran management team, the analyst tells investors in a research note. The firm says Avalo's lead asset AVTX-009 is an IL-1beta antibody in Phase 2 for the treatment of moderate to severe hidradenitis suppurativa with topline data expected in 2026. It thinks AVTX-009 is de-risked in part by lutikizumab data and that Avalo has an angle to show a differentiated profile.
Stifel
Alex Thompson
Strong Buy
Initiates
$36
2025-03-25
Reason
Stifel
Alex Thompson
Price Target
$36
2025-03-25
Initiates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Avalo Therapeutics Inc (AVTX.O) is -2.99, compared to its 5-year average forward P/E of -2.30. For a more detailed relative valuation and DCF analysis to assess Avalo Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.30
Current PE
-2.99
Overvalued PE
-0.31
Undervalued PE
-4.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
-13.84
Current PS
0.00
Overvalued PS
1113.62
Undervalued PS
-1141.29
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 829.12% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

AVTX News & Events

Events Timeline

(ET)
2025-11-06
07:26:11
Avalo Therapeutics Announces Q3 EPS of $2.19, Exceeding Consensus Estimate of $1.64
select
2025-10-29 (ET)
2025-10-29
07:18:00
Avalo Therapeutics finishes participant enrollment for Phase 2 LOTUS trial
select
2025-10-01 (ET)
2025-10-01
07:13:28
Avalo Therapeutics names Boyd as Chief Business Officer and Ivanowicz as Senior Vice President of Human Resources.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-18Newsfilter
Avalo Therapeutics Reveals Inducement Grants for New Hires in Accordance with Nasdaq Listing Rule 5635(c)(4)

  • Inducement Equity Awards: Avalo Therapeutics granted inducement equity awards in the form of nonstatutory stock options to three new employees, totaling 114,000 shares, as part of their employment agreements.

  • Vesting Schedule: The stock options will vest over four years, with 25% vesting on the one-year anniversary of each employee's start date, followed by monthly vesting of the remaining shares.

  • Company Focus: Avalo Therapeutics is dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, with its lead asset, AVTX-009, currently in a Phase 2 clinical trial for hidradenitis suppurativa.

  • Forward-Looking Statements: The press release includes forward-looking statements that are subject to risks and uncertainties, which may affect the actual results compared to the company's projections and expectations.

[object Object]
Preview
9.0
10-29Newsfilter
Avalo Therapeutics Completes Patient Enrollment in Phase 2 LOTUS Trial for AVTX-009 Targeting Hidradenitis Suppurativa Treatment

  • Enrollment Completion: Avalo Therapeutics has completed enrollment in its Phase 2 LOTUS trial for AVTX-009, targeting approximately 250 adults with hidradenitis suppurativa (HS), surpassing the initial goal of 222 patients.

  • Trial Details: The LOTUS trial is a randomized, double-blind, placebo-controlled study assessing the efficacy, safety, and tolerability of AVTX-009, with primary and secondary endpoints focused on clinical response and various severity measures.

  • Company Commitment: Avalo Therapeutics is dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, with AVTX-009 being their lead asset currently in clinical trials.

  • Forward-Looking Statements: The press release includes forward-looking statements regarding Avalo's plans and potential risks, emphasizing the uncertainties in drug development and market conditions.

[object Object]
Preview
3.0
10-02NASDAQ.COM
DFAS's Assets May Indicate a 15% Profit Opportunity

  • ETF Analysis: The Dimensional US Small Cap ETF (DFAS) has an implied analyst target price of $78.84 per unit, indicating a potential upside of 14.91% from its current trading price of $68.61.

  • Notable Holdings: Key underlying holdings with significant upside potential include Precision Biosciences Inc (DTIL) with a target price 440.44% higher than its current price, Avalo Therapeutics Inc (AVTX) with a 159.77% upside, and Cineverse Corp (CNVS) with a 149.27% potential increase.

  • Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that further investor research is needed to assess the validity of these targets.

  • Market Sentiment: A high target price relative to a stock's trading price may indicate optimism but could also lead to potential downgrades if the targets do not align with recent developments in the companies or their industries.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Avalo Therapeutics Inc (AVTX) stock price today?

The current price of AVTX is 17.95 USD — it has increased 5.77 % in the last trading day.

arrow icon

What is Avalo Therapeutics Inc (AVTX)'s business?

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).

arrow icon

What is the price predicton of AVTX Stock?

Wall Street analysts forecast AVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTX is 37.00 USD with a low forecast of 25.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Avalo Therapeutics Inc (AVTX)'s revenue for the last quarter?

Avalo Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Avalo Therapeutics Inc (AVTX)'s earnings per share (EPS) for the last quarter?

Avalo Therapeutics Inc. EPS for the last quarter amounts to -2.19 USD, decreased -22.61 % YoY.

arrow icon

What changes have occurred in the market's expectations for Avalo Therapeutics Inc (AVTX)'s fundamentals?

The market is revising No Change the revenue expectations for Avalo Therapeutics, Inc. (AVTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 54.74%.
arrow icon

How many employees does Avalo Therapeutics Inc (AVTX). have?

Avalo Therapeutics Inc (AVTX) has 23 emplpoyees as of December 05 2025.

arrow icon

What is Avalo Therapeutics Inc (AVTX) market cap?

Today AVTX has the market capitalization of 325.50M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free